Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Proc Natl Acad Sci U S A ; 119(3)2022 01 18.
Article in English | MEDLINE | ID: mdl-35027453

ABSTRACT

Paneth cells are intestinal epithelial cells that release antimicrobial peptides, such as α-defensin as part of host defense. Together with mesenchymal cells, Paneth cells provide niche factors for epithelial stem cell homeostasis. Here, we report two subtypes of murine Paneth cells, differentiated by their production and utilization of fucosyltransferase 2 (Fut2), which regulates α(1,2)fucosylation to create cohabitation niches for commensal bacteria and prevent invasion of the intestine by pathogenic bacteria. The majority of Fut2- Paneth cells were localized in the duodenum, whereas the majority of Fut2+ Paneth cells were in the ileum. Fut2+ Paneth cells showed higher granularity and structural complexity than did Fut2- Paneth cells, suggesting that Fut2+ Paneth cells are involved in host defense. Signaling by the commensal bacteria, together with interleukin 22 (IL-22), induced the development of Fut2+ Paneth cells. IL-22 was found to affect the α-defensin secretion system via modulation of Fut2 expression, and IL-17a was found to increase the production of α-defensin in the intestinal tract. Thus, these intestinal cytokines regulate the development and function of Fut2+ Paneth cells as part of gut defense.


Subject(s)
Cytokines/metabolism , Fucosyltransferases/metabolism , Gastrointestinal Microbiome/physiology , Paneth Cells/metabolism , Animals , Fucosyltransferases/genetics , Ileum , Interleukin-17/metabolism , Interleukins/metabolism , Mice , Symbiosis , alpha-Defensins/metabolism , Interleukin-22 , Galactoside 2-alpha-L-fucosyltransferase
2.
Auris Nasus Larynx ; 51(4): 625-630, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38626696

ABSTRACT

OBJECTIVE: This study aimed to examine the characteristics of nasal and imaging findings of sinonasal lesions in granulomatosis with polyangiitis (GPA) patients and how these lesions change over time in both the active and remission phases of the disease. METHODS: We retrospectively reviewed GPA patients with sinonasal lesions who were followed up at our department between January 2005 and December 2020. The following data were collected: age, sex, symptoms at initial presentation, anti-neutrophil cytoplasmic antibody (ANCA) type, and histopathological, nasal (initial and follow-up), and imaging (initial and follow-up) findings. RESULTS: This study included 17 patients with GPA aged 30 to 79 years. Computed tomography (CT) of the sinuses showed mucosal thickening in 16 patients, bone thickening in 12, bone destruction in 4, and an orbital invasion mass in 3 at the time of diagnosis. After initiating treatment, mucosal thickening of the sinuses improved in 3 of 16 patients and remained unchanged in 13. Bone thickening at the time of diagnosis remained unchanged in 10 of 12 patients and worsened in 2; 1 patient displayed newly developed bone thickening. Destructive nasal findings on CT were positive for proteinase 3-ANCA. CONCLUSIONS: Our study revealed that mucosal thickening, bone thickening, bone destruction, and orbital invasion mass were major CT findings in patients with GPA. Intranasal findings such as granulations, crusting, and necrosis were seen in the active phase; moreover, saddle nose, loss of turbinate, and nasal septal perforation were subsequently seen in the course of the disease. Sinonasal findings of GPA vary depending on the disease stage and period.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic , Granulomatosis with Polyangiitis , Nasal Mucosa , Tomography, X-Ray Computed , Humans , Middle Aged , Granulomatosis with Polyangiitis/complications , Granulomatosis with Polyangiitis/diagnostic imaging , Granulomatosis with Polyangiitis/pathology , Male , Female , Retrospective Studies , Aged , Adult , Antibodies, Antineutrophil Cytoplasmic/immunology , Nasal Mucosa/pathology , Nasal Mucosa/diagnostic imaging , Paranasal Sinuses/diagnostic imaging , Paranasal Sinuses/pathology , Myeloblastin/immunology , Paranasal Sinus Diseases/diagnostic imaging , Paranasal Sinus Diseases/etiology , Paranasal Sinus Diseases/pathology
3.
Pathog Dis ; 812023 Jan 17.
Article in English | MEDLINE | ID: mdl-37833235

ABSTRACT

Nontypeable Haemophilus influenzae (NTHi) is considered a major pathogen underlying middle ear infection. This study aimed to investigate the impact of IL-17 on chronic otitis media (COM) induced by NTHi in mice. NTHi was inoculated into the tympanic bulla with eustachian tubal obstruction. Middle ear effusions (MEEs) and tissues were collected on days 3, 14, and at 1, 2, and 6 months after injection. The expression of interleukin-17A (IL-17A) in MEEs was significantly elevated compared to that in the control group at the translational and transcriptional levels during the experiments. The quantities of IL-17-producing ƎĀ³ĆŽĀ“ T cells were significantly increased compared to that in the control group during COM, but that of Th17 cells did not. Depletion of ƎĀ³ĆŽĀ“ T cells by anti-ƎĀ³ĆŽĀ“ T-cell receptor (TCR) monoclonal antibody (mAb) administration significantly decreased the bacteria counts and the concentrations of IL-1Ɵ, IL-6, IL-17A, TNF-α, and IL-10 in MEEs. Our results suggest that IL-17 may play an important role in prolonging the inflammation in the middle ear in COM and that IL-17-producing ƎĀ³ĆŽĀ“ T cells may contribute to the exacerbated inflammatory response in the middle ear. In this study, anti-ƎĀ³ĆŽĀ“ TCR mAb administration was found to improve chronic middle ear inflammatory conditions.


Subject(s)
Haemophilus Infections , Otitis Media with Effusion , Otitis Media , Animals , Mice , Haemophilus Infections/microbiology , Haemophilus influenzae , Interleukin-17 , Otitis Media/microbiology , Otitis Media with Effusion/microbiology , Receptors, Antigen, T-Cell , T-Lymphocytes
4.
NPJ Vaccines ; 8(1): 106, 2023 Jul 24.
Article in English | MEDLINE | ID: mdl-37488116

ABSTRACT

Respiratory syncytial virus (RSV) is a leading cause of upper and lower respiratory tract infection, especially in children and the elderly. Various vaccines containing the major transmembrane surface proteins of RSV (proteins F and G) have been tested; however, they have either afforded inadequate protection or are associated with the risk of vaccine-enhanced disease (VED). Recently, F protein-based maternal immunization and vaccines for elderly patients have shown promising results in phase III clinical trials, however, these vaccines have been administered by injection. Here, we examined the potential of using the ectodomain of small hydrophobic protein (SHe), also an RSV transmembrane surface protein, as a nasal vaccine antigen. A vaccine was formulated using our previously developed cationic cholesteryl-group-bearing pullulan nanogel as the delivery system, and SHe was linked in triplicate to pneumococcal surface protein A as a carrier protein. Nasal immunization of mice and cotton rats induced both SHe-specific serum IgG and mucosal IgA antibodies, preventing viral invasion in both the upper and lower respiratory tracts without inducing VED. Moreover, nasal immunization induced greater protective immunity against RSV in the upper respiratory tract than did systemic immunization, suggesting a critical role for mucosal RSV-specific IgA responses in viral elimination at the airway epithelium. Thus, our nasal vaccine induced effective protection against RSV infection in the airway mucosa and is therefore a promising vaccine candidate for further development.

5.
Front Immunol ; 13: 819859, 2022.
Article in English | MEDLINE | ID: mdl-35874779

ABSTRACT

Nontypeable Haemophilus influenzae (NTHi) strains form a major group of pathogenic bacteria that colonizes the nasopharynx and causes otitis media in young children. At present, there is no licensed vaccine for NTHi. Because NTHi colonizes the upper respiratory tract and forms biofilms that cause subsequent infectious events, a nasal vaccine that induces NTHi-specific secretory IgA capable of preventing biofilm formation in the respiratory tract is desirable. Here, we developed a cationic cholesteryl pullulan-based (cCHP nanogel) nasal vaccine containing the NTHi surface antigen P6 (cCHP-P6) as a universal vaccine antigen, because P6 expression is conserved among 90% of NTHi strains. Nasal immunization of mice with cCHP-P6 effectively induced P6-specific IgA in mucosal fluids, including nasal and middle ear washes. The vaccine-induced P6-specific IgA showed direct binding to the NTHi via the surface P6 proteins, resulting in the inhibition of NTHi biofilm formation. cCHP-P6 nasal vaccine thus protected mice from intranasal NTHi challenge by reducing NTHi colonization of nasal tissues and eventually eliminated the bacteria. In addition, the vaccine-induced IgA bound to different NTHi clinical isolates from patients with otitis media and inhibited NTHi attachment in a three-dimensional in vitro model of the human nasal epithelial surface. Therefore, the cCHP-P6 nanogel nasal vaccine induced effective protection in the airway mucosa, making it a strong vaccine candidate for preventing NTHi-induced infectious diseases, such as otitis media, sinusitis, and pneumonia.


Subject(s)
Haemophilus Infections , Haemophilus Vaccines , Otitis Media , Animals , Antibodies, Bacterial , Bacterial Outer Membrane Proteins , Child , Child, Preschool , Haemophilus influenzae , Humans , Immunoglobulin A , Mice , Mice, Inbred BALB C , Nanogels , Otitis Media/prevention & control
6.
Microbiol Immunol ; 55(8): 574-81, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21605159

ABSTRACT

Nasal vaccination is an effective therapeutic means of preventing upper respiratory infection. Recently, nasal vaccination with P6 outer membrane protein of nontypeable Haemophilus influenzae (NTHi) and alpha-galactosylceramide (α-GalCer) was reported to induce NTHi-specific protective immunity. The present study investigated the role of the Th17 cells induced by nasal vaccination. Mice were immunized with P6 and α-GalCer, and their P6-specific immune responses were examined. Cytokine-producing cells were analyzed by flow cytometry, and expression of cytokines in P6-specific CD4+ T cells was determined by reverse transcription-polymerase chain reaction. Bacterial challenges were performed with live NTHi. To examine the role of Th17 cells, bacterial clearance was also evaluated after interleukin (IL)-17 neutralization. P6-specific nasal wash immunoglobulin (Ig) A and serum IgG were increased after immunization with P6 and α-GalCer. Specific IgA-producing cells increased markedly in the nasal passages (NPs) of the immunized mice. In addition to P6-specific Th1 and Th2 cells, IL-17-producing Th17 cells were induced in the NPs and spleen. Bacterial clearance was enhanced by nasal vaccination. Interestingly, impaired NTHi clearance was shown after IL-17 neutralization. These findings suggest that nasal vaccination with P6 and α-GalCer is an effective regimen for the induction of NTHi-specific protective immunity in the upper respiratory tract. In addition to antigen-specific secretory-IgA, specific Th17 cells induced by nasal vaccination contribute to protection against NTHi.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Bacterial Outer Membrane Proteins/immunology , Galactosylceramides/administration & dosage , Haemophilus Vaccines/immunology , Th17 Cells/immunology , Administration, Intranasal , Animals , Antibodies, Bacterial/analysis , Antibodies, Bacterial/blood , Bacterial Outer Membrane Proteins/administration & dosage , Blood/immunology , CD4-Positive T-Lymphocytes/immunology , Cytokines/biosynthesis , Disease Models, Animal , Flow Cytometry , Haemophilus Infections/immunology , Haemophilus Infections/prevention & control , Haemophilus Vaccines/administration & dosage , Haemophilus influenzae/immunology , Haemophilus influenzae/pathogenicity , Immunity , Immunoglobulin A/analysis , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Nasal Mucosa/immunology , Reverse Transcriptase Polymerase Chain Reaction , Rodent Diseases/immunology , Rodent Diseases/prevention & control , Vaccination/methods
7.
Vaccine ; 39(25): 3353-3364, 2021 06 08.
Article in English | MEDLINE | ID: mdl-34016473

ABSTRACT

Current polysaccharide-based pneumococcal vaccines are effective but not compatible with all serotypes of Streptococcus pneumoniae. We previously developed an adjuvant-free cationic nanogel nasal vaccine containing pneumococcal surface protein A (PspA), which is expressed on the surfaces of all pneumococcal serotypes. Here, to address the sequence diversity of PspA proteins, we formulated a cationic nanogel-based trivalent pneumococcal nasal vaccine and demonstrated the vaccine's immunogenicity and protective efficacy in macaques by using a newly developed nasal spray device applicable to humans. Nasal vaccination of macaques with cationic cholesteryl pullulan nanogel (cCHP)-trivalent PspA vaccine effectively induced PspA-specific IgGs that bound to pneumococcal surfaces and triggered complement C3 deposition. The immunized macaques were protected from pneumococcal intratracheal challenge through both inhibition of lung inflammation and a dramatic reduction in the numbers of bacteria in the lungs. These results demonstrated that the cCHP-trivalent PspA vaccine is an effective candidate vaccine against pneumococcal infections.


Subject(s)
Pneumococcal Infections , Streptococcus pneumoniae , Animals , Antibodies, Bacterial , Bacterial Proteins , Humans , Macaca , Mice , Mice, Inbred BALB C , Nanogels , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines
8.
Allergy Rhinol (Providence) ; 2(1): 16-20, 2011 Jan.
Article in English | MEDLINE | ID: mdl-22852110

ABSTRACT

Inverted papilloma (IP) is a common benign tumor in the nose and sinus. Osteogenesis in sinonasal IP is extremely rare; to date, only five cases of IP with new bone formation appear in the literature. In addition, the mechanism of osteogenesis in IP remains unclear. Here, we describe three cases of IP with new bone formation and an investigation into a possible role for bone morphogenic protein (BMP) in osteogenesis. Of three patients with sinonasal IP with new bone formation, two were treated by endoscopic sinus surgery and one was followed up with watchful waiting. Tumor tissues were subjected to immunohistochemistry to detect BMP expression. The patients were successfully treated surgically and showed no evidence of recurrence postoperatively. Follow-up examination is ongoing. Immunohistochemically, the tumors expressed BMP-4 but not BMP-2 or BMP-7. ESS could be successfully used to achieve complete removal of the sinonasal IPs with new bone formation. BMP-4 might be associated with new bone formation in the tumor.

9.
Vaccine ; 29(10): 1881-90, 2011 Feb 24.
Article in English | MEDLINE | ID: mdl-21237276

ABSTRACT

Nasal vaccination is an effective therapeutic regimen for preventing upper respiratory infection, while DNA vaccines represent a new approach for controlling infectious diseases. Here, we examined the efficacy of nasally administered DNA vaccine on upper respiratory infections. A DNA plasmid encoding the P6 outer membrane protein of nontypeable Haemophilus influenzae (NTHi) was constructed. Mice were immunized 3 times intranasally with the DNA plasmid and Matrix-M, an immunostimulatory complex adjuvant. P6-specific immune responses were examined using purified P6 protein. Nasal-associated lymphoid tissue (NALT) CD4(+) T cells were purified and incubated with feeder cells in the presence of P6, and the expression of cytokine mRNA was examined. In addition, NTHi challenges were performed and the level of NTHi was quantified in nasal washes. P6-specific nasal wash IgA and serum IgG were elevated following immunization with the DNA plasmid and Matrix-M. The number of specific IgA-producing cells increased in the nasal passages of the immunized mice. In addition to Th1 and Th2 cytokine expression, IL-17 was detected in P6-specific NALT CD4(+) T cells. Moreover, DNA vaccination enhanced bacterial clearance. These findings suggest that a successful DNA vaccination protocol has been developed for inducing in vivo immune responses against NTHi. Nasal vaccination with P6 DNA vaccine and Matrix-M might be a new effective regimen for the induction of specific protective immunity in the upper respiratory tract.


Subject(s)
Bacterial Outer Membrane Proteins/immunology , Haemophilus Vaccines/immunology , Haemophilus influenzae/immunology , ISCOMs/immunology , Nasopharynx/immunology , Vaccination/methods , Vaccines, DNA/immunology , Animals , Antibodies, Bacterial/analysis , Bacterial Load , Bacterial Outer Membrane Proteins/genetics , CD4-Positive T-Lymphocytes/immunology , Cells, Cultured , Cytokines/biosynthesis , Disease Models, Animal , Haemophilus Infections/immunology , Haemophilus Infections/microbiology , Haemophilus Vaccines/administration & dosage , Haemophilus Vaccines/genetics , Haemophilus influenzae/genetics , ISCOMs/administration & dosage , Immunity, Mucosal , Immunization, Secondary/methods , Immunoglobulin A/analysis , Immunoglobulin G/analysis , Mice , Mice, Inbred BALB C , Nasal Mucosa/immunology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Vaccines, DNA/administration & dosage
10.
Vaccine ; 28(31): 5068-74, 2010 Jul 12.
Article in English | MEDLINE | ID: mdl-20478344

ABSTRACT

The efficacy of alpha-galactosylceramide (alpha-GalCer) as a mucosal adjuvant was examined. Mice were immunized intranasally with nontypeable Haemophilus influenzae (NTHi) P6 protein and alpha-GalCer. P6-specific antibody responses in the form of P6-specific IgA in nasal washes and serum IgG titers were significantly elevated. Splenic CD4(+) T cells expressed P6-specific Th1 and Th2 cytokine mRNA. In addition, NTHi was quantified in nasal washes following NTHi challenges, and the clearance of NTHi from the nasopharynx was also enhanced. These results indicate that alpha-GalCer might be an effective mucosal adjuvant.


Subject(s)
Bacterial Outer Membrane Proteins/immunology , Dendritic Cells/immunology , Galactosylceramides/immunology , Haemophilus Infections/prevention & control , Haemophilus Vaccines/immunology , Natural Killer T-Cells/immunology , Adjuvants, Immunologic/pharmacology , Administration, Intranasal , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antibody Formation , CD4-Positive T-Lymphocytes/immunology , Haemophilus Infections/immunology , Haemophilus influenzae/immunology , Immunity, Mucosal , Immunoglobulin A/immunology , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Nasopharynx/immunology
SELECTION OF CITATIONS
SEARCH DETAIL